Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options

References

• Jemal A, Siegel R, Ward E, et al Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematology Am Soc Hematol Educ Program 2005:285–291.
   PubMedGoogle Scholar
• Hallek M, Fingerle-Rowson G, Fink A, et al E. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009;114(Suppl. 1): 223 (Abstract 535).
   Google Scholar
• Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007;33:710–728.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Kontoyiannis D, et al Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755–1762.
   PubMed Web of Science ®Google Scholar
• May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999;18:7621–7636.
   PubMed Web of Science ®Google Scholar
• Wright SJ, Robertson LE, O'Brien S, Plunkett W, Keating MJ. The role of fludarabine in hematological malignancies. Blood Rev 1994;8:125–134.
   PubMed Web of Science ®Google Scholar
• Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003;10:477–484.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, et al Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711–1720.
   PubMed Web of Science ®Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450–456.
   PubMedGoogle Scholar
• Anaissie EJ, Kontoyiannis DP, O'Brien S, et al Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559–566.
   PubMed Web of Science ®Google Scholar
• Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:2033–2039.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 1994;34:30–36.
   PubMed Web of Science ®Google Scholar
• Giles FJ, O'Brien SM, Santini V, et al Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 1999;36:57–65.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Cortes J, et al Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414–1420.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Estey E, et al Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994;330:319–322.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson B, Piro L, et al A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003;17:323–327.
   PubMed Web of Science ®Google Scholar
• Weiss MA, Maslak PG, Jurcic JG, et al Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003;21:1278–1284.
   PubMed Web of Science ®Google Scholar
• Willis CR, Goodrich A, Park K, et al A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Ann Hematol 2006;85:301–307.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580–3589.
   PubMed Web of Science ®Google Scholar
• Hussein MA, Gundacker H, Head DR, et al Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706. Leukemia 2005;19:1880–1886.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327:1056–1061.
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinka-Morawiec M, Krykowski E, et al Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996;22:509–514.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Zanzig C, et al Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995;13:983–988.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, et al Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575–1581.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196–203.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475–476.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S, et al A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006;106:337–345.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, et al Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Falkner A, Hopfinger G, et al Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006;107:2408–2416.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024–7031.
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Lucas MS, et al Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005;19:1207–1210.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Ravandi F, Riehl T, et al Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816–1819.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452–453.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Kennedy B, Rawstron A, Carter C, et al Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245–2247.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Lerner S, et al The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931–1939.
   PubMed Web of Science ®Google Scholar
• Elter T, James R, Stilgenbauer S, Boettcher S, Ritgen M, Doehner H. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. Blood 2009;114(Suppl. 1): 92 (Abstract 209).
   Google Scholar
• Engert A, Gercheva L, Robak T, et al Improved progression-free survival (PFS) of alemtuzumab (Campath®, MabCampath®) plus fludarabine (Fludara®) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood 2009;114(Suppl. 1): 224 (Abstract 537).
   Google Scholar
• Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2004;18:915–926, x.
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Khouri IF, Haagenson M, et al Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 2005;23:5788–5794.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002;4:217–221.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, et al Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28–35.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Sandmaier BM, et al Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:3819–3829.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Sandmaier BM, et al Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912–4920.
   PubMed Web of Science ®Google Scholar
• Dreger P, Corradini P, Kimby E, et al Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12–17.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Bartlett N, et al Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253–1257.
   PubMed Web of Science ®Google Scholar
• Lin T, Heerema N, Lozanski G, et al Flavopiridol (alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008;112(Suppl. 1): 23 (Abstract 46).
   Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
   PubMed Web of Science ®Google Scholar
• Andritsos L, Fischer B, Lin T, et al Low incidence of opportunistic infections in CLL patients treated with single agent flavopiridol. Blood 2007;110(Suppl. 1): 920A (Abstract 3128).
   Google Scholar
• Teeling JL, French RR, Cragg MS, et al Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094–1100.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Kipps T, Österborg A, Mayer J, et al Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy. J Clin Oncol 2009;27: Abstract 7043.
   Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, et al Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618–621.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, et al Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519–2255.
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849–1859.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Gowda A, Joshi T, et al The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848–855.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Czuczman M, Padmanabhan S, et al Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. Blood 2007;110(Suppl. 1): 914A (Abstract 3108).
   PubMed Web of Science ®Google Scholar
• Wendtner C, Mahadevan D, Stilgenbauer S, et al Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. Blood 2008;112(Suppl. 1): 732 (Abstract 2104).
   Google Scholar
• Badoux X, Reuben J, Lee B, et al Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lyphocytic leukaemia. Haematologica 2009;94(Suppl. 3): Abstract 10.31.
   Google Scholar
• Ferrajoli A, O'Brien S, Wierda W, et al Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): 23 (Abstract 45).
   PubMed Web of Science ®Google Scholar
• Chen C, Paul H, Xu W, et al A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): 23 (Abstract 44).
   Google Scholar
• Ferrajoli A, Badoux X, O'Brien S, et al Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): 89 (Abstract 206).
   Google Scholar